More articles from Metabolism, Transport, and Pharmacogenetics

You have access
The Effects of Indobufen on Micro-Inflammation and Peritoneal Transport Function in Patients Undergoing Continuous Ambulate Peritoneal Dialysis: A Prospective Randomized Controlled Study
Fang Liu, Hao Zhang, Hong Wu, Shikun Yang, Jun Liu and Jianwen Wang

Journal of Pharmacology and Experimental Therapeutics February 2023, 384 (2) 296-305; DOI: https://doi.org/10.1124/jpet.122.001138
Open Access
Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors
Terry Podoll, Paul G. Pearson, Allard Kaptein, Jerry Evarts, Gerjan de Bruin, Maaike Emmelot-van Hoek, Anouk de Jong, Bart van Lith, Hao Sun, Stephen Byard, Adrian Fretland, Niels Hoogenboom, Tjeerd Barf and J. Greg Slatter

Journal of Pharmacology and Experimental Therapeutics January 2023, 384 (1) 173-186; DOI: https://doi.org/10.1124/jpet.122.001116
You have access
Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors
Surabhi Talele, Wenjuan Zhang, Jiajia Chen, Shiv K. Gupta, Danielle M. Burgenske, Jann N. Sarkaria and William F. Elmquist

Journal of Pharmacology and Experimental Therapeutics October 2022, 383 (1) 91-102; DOI: https://doi.org/10.1124/jpet.122.001230
You have access
Murine Central Nervous System and Bone Marrow Distribution of the Aurora A Kinase Inhibitor Alisertib: Pharmacokinetics and Exposure at the Sites of Efficacy and Toxicity
Ju-Hee Oh, Erica A. Power, Wenjuan Zhang, David J. Daniels and William F. Elmquist

Journal of Pharmacology and Experimental Therapeutics October 2022, 383 (1) 44-55; DOI: https://doi.org/10.1124/jpet.122.001268
Open Access
Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane
Irina Teslenko, Julia Trudeau, Shaman Luo, Christy J.W. Watson, Gang Chen, Cristina I. Truica and Philip Lazarus

Journal of Pharmacology and Experimental Therapeutics September 2022, 382 (3) 327-334; DOI: https://doi.org/10.1124/jpet.122.001232
You have access
Impact of SLC43A3/ENBT1 Expression and Function on 6-Mercaptopurine Transport and Cytotoxicity in Human Acute Lymphoblastic Leukemia Cells
Nicholas M. Ruel, Khanh Hoa Nguyen, Chan S. Kim, Laura P.S. Andrade and James R. Hammond

Journal of Pharmacology and Experimental Therapeutics September 2022, 382 (3) 335-345; DOI: https://doi.org/10.1124/jpet.122.001155
You have access
Influence of CYP2B6 Pharmacogenetics on Stereoselective Inhibition and Induction of Bupropion Metabolism by Efavirenz in Healthy Volunteers
Brandon T. Gufford, Ingrid F. Metzger, Nadia O. Bamfo, Eric A. Benson, Andrea R. Masters, Jessica Bo Li Lu and Zeruesenay Desta

Journal of Pharmacology and Experimental Therapeutics September 2022, 382 (3) 313-326; DOI: https://doi.org/10.1124/jpet.122.001277
You have access
Physiological Characterization of the Transporter-Mediated Uptake of the Reversible Male Contraceptive H2-Gamendazole Across the Blood-Testis Barrier
Raymond K. Hau, Joseph S. Tash, Gunda I. Georg, Stephen H. Wright and Nathan J. Cherrington

Journal of Pharmacology and Experimental Therapeutics September 2022, 382 (3) 299-312; DOI: https://doi.org/10.1124/jpet.122.001195
You have access
Zhx2 Is a Candidate Gene Underlying Oxymorphone Metabolite Brain Concentration Associated with State-Dependent Oxycodone Reward
Jacob A. Beierle, Emily J. Yao, Stanley I. Goldstein, William B. Lynch, Julia L. Scotellaro, Anyaa A. Shah, Katherine D. Sena, Alyssa L. Wong, Colton L. Linnertz, Olga Averin, David E. Moody, Christopher A. Reilly, Gary Peltz, Andrew Emili, Martin T. Ferris and Camron D. Bryant

Journal of Pharmacology and Experimental Therapeutics August 2022, 382 (2) 167-180; DOI: https://doi.org/10.1124/jpet.122.001217
You have access
Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban
Lloyd Wei Tat Tang, Guoyi Wu and Eric Chun Yong Chan

Journal of Pharmacology and Experimental Therapeutics August 2022, 382 (2) 123-134; DOI: https://doi.org/10.1124/jpet.122.001222

Main menu

User menu

Search

More articles from Metabolism, Transport, and Pharmacogenetics

Pages

Navigate

More Information

ASPET's Other Journals